Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MAIA Biotechnology, Inc.

Get SEC filing alerts via email and in your feed for MAIA Biotechnology, Inc.

MAIA

MAIA Biotechnology, Inc.

About MAIA Biotechnology, Inc.

Maia Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies and telomere-targeting agents for cancer. Its lead candidate, THIO, aims to treat various solid tumors, including non-small cell lung cancer, by disrupting telomeres and activating immune responses. The company leverages proprietary technology, strategic collaborations, and a robust patent portfolio to advance innovative cancer treatments across multiple indications and markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from MAIA Biotechnology, Inc.

1
1
MAIA Biotechnology, Inc. MAIA Biotechnology Reports $6.37 Million Net Loss and $34.41 Million Cash Reserves in Latest 10-Q

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
MAIA Biotechnology, Inc. MAIA Biotechnology Reports $22.4 Million Net Loss, Highlights Clinical Advancements for Ateganosine

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
MAIA Biotechnology, Inc. MAIA Biotechnology Reports $8.9 Million Net Loss in Latest Quarter, Increases Investment in Clinical Trials

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MAIA Biotechnology, Inc. MAIA Biotechnology Reports 40% Improvement in Q2 Net Loss, Advances Clinical Trials

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MAIA Biotechnology, Inc. MAIA Biotechnology Reports Improved Net Loss of $4.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MAIA Biotechnology, Inc. MAIA Biotechnology Reports Increased Net Loss and Clinical Trial Developments for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
MAIA Biotechnology, Inc. MAIA Biotechnology Reports Improved Cash Position, Reduced Operating Expenses, and Increased Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments